The board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 HKD | -1.27% | +0.87% | -5.87% |
08:46am | SSY Group Gets Chinese Regulator’s Approval for Drug Production, Registration | MT |
May. 30 | SSY Group's Trelagliptin Succinate Gets Bulk Drug Approval in China | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.87% | 1.79B | |
+42.31% | 739B | |
+32.34% | 598B | |
-5.77% | 353B | |
+17.90% | 318B | |
+3.34% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.34% | 164B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market